Management of coeliac disease patients after the confirmation of diagnosis in Central Europe

Eur J Gastroenterol Hepatol. 2022 Jan 1;34(1):27-32. doi: 10.1097/MEG.0000000000002039.

Abstract

Background: Recently published paediatric guidelines for diagnosing coeliac disease do not include recommendations on the follow-up of coeliac disease patients.

Goal: The aim of this study was to assess the management practices and experience of coeliac disease patients with their follow-up appointments in Central Europe.

Study: Gastroenterologists and coeliac disease patients in five Central European countries were asked to complete the web-based questionnaire focusing on coeliac disease management practices.

Results: Answers from 147 gastroenterologists and 2041 coeliac disease patients were available for the analysis. More than half of the gastroenterologists (58.5%) schedule the first follow-up visit within 3 months after the diagnosis. At follow-up, tissue transglutaminase antibodies are checked in almost all patients (95.9%). Approximately two-thirds (60.7%) of gastroenterologists refer all of their patients to the dietitian at diagnosis. Similarly, 42.8% of coeliac disease patients reported that they had not been appointed to a dietitian. Almost one-third of coeliac disease patients (30.8%) reported that they had no follow-up appointments with gastroenterologist at all.

Conclusions: Follow-up of coeliac disease patients is suboptimal in Central Europe. Many patients are not followed regularly. A lot of patients are not referred to a dietitian. The recommendations on the optimal follow-up of coeliac disease patients are needed in order to improve patient care.

MeSH terms

  • Autoantibodies
  • Celiac Disease* / diagnosis
  • Celiac Disease* / epidemiology
  • Celiac Disease* / therapy
  • Child
  • Europe
  • Gastroenterologists*
  • Humans
  • Referral and Consultation
  • Transglutaminases

Substances

  • Autoantibodies
  • Transglutaminases